Methionitazene

Pharmaceutical compound From Wikipedia, the free encyclopedia

Methionitazene (methylthionitazene) is a benzimidazole derivative which is an opioid designer drug. It was invented in the late 1950s as part of the original research into the "nitazene" group of opioids by CIBA in Switzerland, but as with all compounds from this group was never developed for legitimate medical uses. In early studies on mice, it was found to be around half the potency of the methoxy analogue metonitazene with around 50 times the analgesic potency of morphine, and significantly more potent than the ethylthio homologue,[1] but more recent research using modern techniques found methionitazene and metonitazene to have a similar EC50 in vitro despite the methoxy compound having a stronger binding affinity at the mu opioid receptor.[2]

CAS Number
PubChem CID
ChemSpider
UNII
Quick facts Identifiers, CAS Number ...
Methionitazene
Identifiers
  • N,N-diethyl-2-[2-[(4-methylsulfanylphenyl)methyl]-5-nitrobenzimidazol-1-yl]ethanamine
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC21H26N4O2S
Molar mass398.53 g·mol−1
3D model (JSmol)
  • CCN(CC)CCN1C2=C(C=C(C=C2)[N+](=O)[O-])N=C1CC3=CC=C(C=C3)SC
  • InChI=1S/C21H26N4O2S/c1-4-23(5-2)12-13-24-20-11-8-17(25(26)27)15-19(20)22-21(24)14-16-6-9-18(28-3)10-7-16/h6-11,15H,4-5,12-14H2,1-3H3
  • Key:ODVCNMQMXRKHGM-UHFFFAOYSA-N
Close

See also

References

Related Articles

Wikiwand AI